一种布鲁氏菌CTL抗原表位肽及其应用

By developing Brucella CTL antigenic epitope peptides and related biomaterials, peptide vaccines and drugs were prepared, solving the problems of virulence reversion and poor immune efficacy of existing vaccines. This resulted in highly safe and effective CTL immune responses, suitable for the prevention and treatment of brucellosis.

CN121319129BActive Publication Date: 2026-07-17INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
INSTITUTE OF ANIMAL SCIENCES OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES
Filing Date
2025-12-11
Publication Date
2026-07-17

Smart Images

  • Figure CN121319129B_ABST
    Figure CN121319129B_ABST
Patent Text Reader

Abstract

本发明公开了一种布鲁氏菌CTL抗原表位肽及其应用，其为以下任一或多个表位多肽，所述表位多肽的氨基酸序列如SEQIDNO.1‑3的所示；本发明精准激活CTL免疫应答，契合布鲁氏菌胞内感染的免疫防御需求，为布鲁氏菌新型亚单位疫苗提供核心成分，规避传统减毒活疫苗毒力返祖、干扰诊断等风险。
Need to check novelty before this filing date? Find Prior Art